QIAO Xue-ying,ZHOU Dao-an,GAO Xian-shu,et al.A prospective clinical study of intracavitary brachytherapy combined with external beam irradiation for esophageal carcinoma[J].Chinese Journal of Radiological Medicine and Protection,2005,25(6):547-550
A prospective clinical study of intracavitary brachytherapy combined with external beam irradiation for esophageal carcinoma
Received:December 12, 2004  
DOI:
KeyWords:Esophageal neoplasms  Radiotherapy  Brachytherapy
FundProject:
Author NameAffiliationE-mail
QIAO Xue-ying Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China xsgao777@hotmail.com 
ZHOU Dao-an 上海肺科医院放疗科  
GAO Xian-shu Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China  
韩春 Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China  
平育敏 050011 石家庄, 河北医科大学第四医院胸外科  
杨香然 Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China  
万钧 Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China  
Hits: 3502
Download times: 1908
Abstract::
      Objective To investigate the effectiveness and side-effects of booster brachytherapy after different doses of external beam irradiation and to determine the proper time for brachytherapy in esophageal carcinoma. Methods One hundred eligible patients with esophadeal carcinoma were randomized into two groups(group A and group B). In group A, an intracavitary booster brachytherapy was given concomitantly with an external beam irradiation(EBI) when the total dose of EBI reached 35 Gy. While in the group B, the intracavitary booster brachytherapy was given just after EBI reached 50 Gy. The total dose of EBI in both groups was 50 Gy (2 Gy per fraction, 1 time a day for 5 days per week). Five Gy of intracavitary brachytherapy was given once a week for 2 times. EBI was not given during the day of brachytherapy. Results The 1-, 3-, 5-year local control rates were respectively 60.2%, 39.8%, 36.2% in group A and 54.1%, 32.8%, 29.2% in group B (P=0.5118) and the 1-, 3-, 5-year survival rates were respectively 52.0%, 26.0%, 21.8% and 54.0%, 23.4%, 16.7% (P=0.8159). The esophagitis rate in group A and group B was 70% and 48% respectively with P=0.038. But the rate of severe esophagitis was the same in the two groups. The fistula rate was 8% and 10%, respectively. Conclusion Intracavitary booster brachytherapy was feasible either after 35 Gy or 50 Gy of EBI in esophageal carcinoma. A higher morbidity of acute esophagitis was observed in group A than in group B. Both protocols are tolerable.
HTML  View Full Text  View/Add Comment  Download reader
Close

Copyright©    Editorial Office of Chinese Journal of Radiological Medicine and Protection    

Beijing ICP No. 05020547 -2

Address: 2 Xinkang Street, Dewai, Beijing 100088, China

Telephone:010-62389620; Email:cjrmp@cjrmp.sina.net

Technical Support:Beijing E-tiller CO.,LTD.

Visitors:11567836  On-line:0

v
Scan QR Code
&et=8AF7311A82183BF79A35DEBCA3C40A96FD7153CB57DF0FDB6EF14A445FCB7847009B277A35E5D27A25344FB2095EB9BC9E2502EA7229F4E78C978491BB86070B9F5033C711513532CB4A25717625372909E5507E0B81152B47189146AF7CD398FEF03F8841776ECEE76FD2F06C8C3CD6FBDD1A30EE5E8749C73E03EB15695325&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=D4D466D60FDC1A5A&jid=5E4353813E091AB841B02B880782B82C&yid=2DD7160C83D0ACED&aid=18B70FBA84587000&vid=&iid=B31275AF3241DB2D&sid=4002B7787911C73B&eid=64808317C39DF331&fileno=20050616&flag=1&is_more=0"> var my_pcid="A9DB1C13C87CE289EA38239A9433C9DC"; var my_cid="D4D466D60FDC1A5A"; var my_jid="5E4353813E091AB841B02B880782B82C"; var my_yid="2DD7160C83D0ACED"; var my_aid="18B70FBA84587000";